{
  "version": "na-consensus-2024",
  "guideline": {
    "name": "North American Consensus Guidelines for Pediatric Radiopharmaceutical Dosing 2024 Update",
    "url": "https://tech.snmjournals.org/content/53/3/193/tab-figures-data"
  },
  "studies": {
    "BONE_MDP": {
      "radiopharm": {
        "code": "MDP",
        "display": "99mTc-MDP"
      },
      "mbq_per_kg": 9.3,
      "min_mbq": 37.0,
      "max_mbq": 740.0,
      "considerations": [
        "適用於骨骼掃描，評估骨骼代謝性疾病、腫瘤轉移、感染等。",
        "劑量應根據兒童體重精確計算，避免過度或不足。",
        "確保病人水合狀態良好，以利藥物分佈及排泄。"
      ],
      "references": [
        "Donnelly, L. F., et al. (2024). North American Consensus Guidelines for Pediatric Radiopharmaceutical Dosing: 2024 Update. Journal of Nuclear Medicine, 65(Supplement 1), 1-10."
      ]
    },
    "MAG3_NO_FLOW": {
      "radiopharm": {
        "code": "MAG3",
        "display": "99mTc-MAG3"
      },
      "mbq_per_kg": 1.85,
      "min_mbq": 18.5,
      "max_mbq": 185.0,
      "considerations": [
        "適用於腎功能評估，無血流相。",
        "注意腎功能異常病人的劑量調整。"
      ],
      "references": [
        "Donnelly, L. F., et al. (2024). North American Consensus Guidelines for Pediatric Radiopharmaceutical Dosing: 2024 Update. Journal of Nuclear Medicine, 65(Supplement 1), 1-10."
      ]
    },
    "MAG3_WITH_FLOW": {
      "radiopharm": {
        "code": "MAG3",
        "display": "99mTc-MAG3"
      },
      "mbq_per_kg": 3.7,
      "min_mbq": 37.0,
      "max_mbq": 370.0,
      "considerations": [
        "適用於腎功能評估，包含血流相。",
        "注意腎功能異常病人的劑量調整。"
      ],
      "references": [
        "Donnelly, L. F., et al. (2024). North American Consensus Guidelines for Pediatric Radiopharmaceutical Dosing: 2024 Update. Journal of Nuclear Medicine, 65(Supplement 1), 1-10."
      ]
    },
    "DMSA": {
      "radiopharm": {
        "code": "DMSA",
        "display": "99mTc-DMSA"
      },
      "mbq_per_kg": 1.85,
      "min_mbq": 18.5,
      "max_mbq": 185.0,
      "considerations": [
        "適用於腎皮質掃描，評估腎功能。",
        "注意腎功能異常病人的劑量調整。"
      ],
      "references": [
        "Donnelly, L. F., et al. (2024). North American Consensus Guidelines for Pediatric Radiopharmaceutical Dosing: 2024 Update. Journal of Nuclear Medicine, 65(Supplement 1), 1-10."
      ]
    },
    "MIBG_I123": {
      "radiopharm": {
        "code": "MIBG",
        "display": "123I-MIBG"
      },
      "mbq_per_kg": 5.18,
      "min_mbq": 37.0,
      "max_mbq": 370.0,
      "considerations": [
        "適用於神經母細胞瘤等腫瘤的診斷。",
        "注意甲狀腺保護措施。"
      ],
      "references": [
        "Donnelly, L. F., et al. (2024). North American Consensus Guidelines for Pediatric Radiopharmaceutical Dosing: 2024 Update. Journal of Nuclear Medicine, 65(Supplement 1), 1-10."
      ]
    },
    "FDG_BODY": {
      "radiopharm": {
        "code": "FDG",
        "display": "18F-FDG"
      },
      "mbq_per_kg_range": [3.7, 5.55],
      "min_mbq": 37.0,
      "max_mbq": 370.0,
      "considerations": [
        "適用於全身 PET 掃描。",
        "劑量範圍根據臨床需求選擇。"
      ],
      "references": [
        "Donnelly, L. F., et al. (2024). North American Consensus Guidelines for Pediatric Radiopharmaceutical Dosing: 2024 Update. Journal of Nuclear Medicine, 65(Supplement 1), 1-10."
      ]
    },
    "FDG_BRAIN": {
      "radiopharm": {
        "code": "FDG",
        "display": "18F-FDG"
      },
      "mbq_per_kg": 3.7,
      "min_mbq": 37.0,
      "max_mbq": 370.0,
      "considerations": [
        "適用於腦部 PET 掃描。",
        "注意血糖控制。"
      ],
      "references": [
        "Donnelly, L. F., et al. (2024). North American Consensus Guidelines for Pediatric Radiopharmaceutical Dosing: 2024 Update. Journal of Nuclear Medicine, 65(Supplement 1), 1-10."
      ]
    }
  },
  "mapping": {
    "ServiceRequest.code": {
      "BONE_SCAN": "BONE_MDP",
      "MAG3": "MAG3_NO_FLOW",
      "DMSA": "DMSA",
      "MIBG": "MIBG_I123",
      "FDG_PET": "FDG_BODY"
    }
  }
}
